Medtronic Q1 revenue $8.58B (+4.8% organic); raises FY26 EPS; adds 2 directors, forms new committees

Medtronic plc

2026-Q1 EPS reported $0.81 revenue$8,578,000,000

Q1 GAAP EPS $0.81; non-GAAP EPS $1.26 (+2%), revenue $8.58B, organic growth 4.8%.
FY26 non-GAAP EPS guidance raised to $5.60-$5.66 from $5.50-$5.60; organic revenue growth ~5% reaffirmed.
Cardiac Ablation Solutions revenue +50% on pulsed field ablation strength; US +72%.
Board expanded to 13; John Groetelaars and William Jellison appointed as independent directors.
New Growth and Operations committees formed; Investor Day planned for mid-2026; engagement with Elliott Management.

item 2.02item 5.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.